mesalamine has been researched along with thalidomide in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kamm, MA | 1 |
| Fleming, A; Goldsmith, P; Jankowski, J | 1 |
| Barone, M; Cantarini, L; Fabiani, C; Franceschini, R; Frediani, B; Galeazzi, M; Iannone, F; Lapadula, G; Lopalco, G; Rigante, D; Venerito, V | 1 |
| Ivagnes, S; Margari, F; Margari, L; Palumbi, R; Petruzzelli, MG | 1 |
3 review(s) available for mesalamine and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Review article: chronic active disease and maintaining remission in Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Chronic Disease; Crohn Disease; Humans; Infliximab; Mercaptopurine; Mesalamine; Methotrexate; Prognosis; Steroids; Thalidomide | 2004 |
Update on the Medical Management of Gastrointestinal Behçet's Disease.
Topics: Adrenal Cortex Hormones; Animals; Behcet Syndrome; Gastrointestinal Tract; Humans; Immunologic Factors; Mesalamine; Sulfasalazine; Thalidomide | 2017 |
6 other study(ies) available for mesalamine and thalidomide
| Article | Year |
|---|---|
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship | 2003 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease: a feasibility study.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Embryo, Nonmammalian; Feasibility Studies; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Intestinal Mucosa; Larva; Mesalamine; Prednisolone; Sesquiterpenes; Thalidomide; Zebrafish | 2010 |
Early onset first-episode psychosis during treatment with thalidomide for refractory ulcerative colitis: a case report.
Topics: Adolescent; Aftercare; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Colitis, Ulcerative; Diagnostic and Statistical Manual of Mental Disorders; Drug Substitution; Episode of Care; Humans; Immunologic Factors; Male; Mesalamine; Neuroimmunomodulation; Psychotic Disorders; Remission Induction; Thalidomide | 2019 |